An 80.9% objective response rate in heavily pre-treated, relapsed or refractory CLL patients — including those already exposed to BTK inhibitors and BCL-2 inhibitors — is the clinical number that explains why Roche just committed $700 million upfront and up to $2.3 billion total to co-develop bexobrutideg with Nurix Therapeutics. That phase 1a signal, drawn from 47 response-evaluable patients as of a March 2025 data cut, puts this oral BTK degrader well above what conventional BTK inhibitors typically show in comparable post-progression populations.
The mechanistic distinction matters enormously here. Ibrutinib’s 2014 accelerated approval in previously treated CLL opened the BTK era, and zanubrutinib has since raised the efficacy ceiling among covalent inhibitors. But both drugs block BTK’s kinase activity while leaving the protein — and its scaffolding function — intact, which is precisely how resistance mutations accumulate over time. Bexobrutideg, by contrast, hijacks the body’s proteasome system to eliminate the BTK protein entirely, stripping out both kinase and scaffolding roles simultaneously. That isn’t a pharmacological nuance; it is the structural reason why patients who have already failed BTK inhibitors are responding at all. Phase 3 initiation in second-line CLL is planned for summer 2026, so confirmatory data will arrive faster than the deal’s milestone ladder might suggest.
What makes this collaboration structurally unusual is the therapeutic sprawl built into the original design. The deal covers not just B-cell malignancies but chronic spontaneous urticaria and multiple sclerosis — two indications where BTK’s role in driving immune dysregulation is established but where no degrader has yet been validated clinically. Roche shoulders 60% of development costs across all three areas, takes full ex-U.S. commercialization responsibility, and splits U.S. profits equally with Nurix. That cost-sharing asymmetry — Nurix at 40% — is notable for a company that still needs to run the phase 3 program while simultaneously funding immunology and neurology exploration.
The CLL market alone is projected to grow from $12 billion in 2024 to $16 billion by 2035, and bexobrutideg’s phase 1a data was generated precisely in the patients who represent that market’s hardest problem: those who have exhausted standard options. The single number worth tracking from this trial forward is the durability endpoint — specifically, progression-free survival in the BTK-pretreated cohort. Response rate opened the door; how long those responses hold will determine whether this degrader earns best-in-class status or merely proves the mechanism works.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
